Skip to main content

Table 2 Details of Patients with Postoperative DVT

From: Prevalence and risk factor of post-operative lower extremities deep vein thrombosis in patients undergoing gynecologic surgery: a single-institute cross-sectional study

sn Age (year) BMI (kg/m2) UD Diagnosis Operation Operation time (min) Perioperative blood transfusion
(unit)
Duration of US (hours) Location of DVT Treatment Note
26 68 25.5 HT,DLP CA colon with ovarian metastasis Interval debulking
TAH and BSO and debulking surgery
150 none 72 Left gastrocnemius vessle Enoxapalin 0.4 ➔ 0.6 ml SC OD LOS 14 days ➔ lost to follow up
44 67 21.8 HT Uterine cancer (stage IV carcinosarcoma) TAH and BSO and debulking surgery 198 2 120 Left soleal vein Enoxapalin
0.5 ml SC q 12 h
3 mos
LOS 12 days ➔ supportive treatment
51 45 23.2 none endometrioma TAH and BSO and lysis of adhesions 224 none 47 Distal right soleal vein Enoxaparin 0.6 ml sc q 12 h 17 days LOS 7 days, off enoxaparin due to bleeding per vaginal stump and FU at 5 weeks after that the DVT was disappeared.
56 42 25.0 HT CA cervix IIIC1(p)
Neuroendocrine tumor
RHPL and BSO 195 none 167 Right soleal vein None
Patient refused treatment
LOS 9 days
67 64 24.8 none CA ovary (Recurrent) Debulking tumor with bowel resection and repair vaginal stump and repair bladder 411 2 306 Both soleal vein Enoxaparin 0.6 ml sc q 12 h for 5 weeks ➔ bemiparin 7500 u sc for 6 months LOS 19 days
111 83 16.2 HT, CAD CA fallopian tube stage IIIA2 TAH with BSO with ascites collection with omentectomy with rectal Bx 80 none 73 Right soleal vein enoxaparin 0.4 ml sc od until now LOS 23 days
  1. SN = Serial number, BMI = Body mass index, UD = Underlying disease, US = Ultrasound, DVT = Deep vein thrombosis, HT = Hypertension, DLP = Dyslipidemia, TAH = Total abdominal hysterectomy, BSO = Bilateral salpingo-oophorectomy, SC = Subcutaneous injection, q = every, hr. = hours, LOS = Length of stay, RHPL = Radical hysterectomy and pelvic lymphadenectomy, CAD = Coronary artery disease, Bx = Biopsy